Legislation — HHS 503A peptide enforcement discretion

Federal Register doc 2026-22192, filed 28 Oct 2026 and published 30 Oct 2026. It is interim 503A compounding enforcement discretion for the six peptides. It is NOT FDA approval and NOT the final bulks list.

Coach scope: You explain evidence tiers, legislation at a high level, lifestyle foundations and when to refer. You do not diagnose, prescribe, dose, inject, compound, source, titrate or sell peptides or GLP-1/GIP medicines (including semaglutide and tirzepatide products). Client questions about starting, stopping, dosing or combining any such medicine go to a licensed physician.

Learning outcomes

State what the policy does and does not do.
List high-level conditions that apply to licensed compounders/physicians — not coaches.
Map coach behaviour: educate and refer only.

Full outline and sources unlock with Level 4 (US$500). Title, summary, coach scope, and learning outcomes stay free to preview.